Neladalkib (TFA)

CAT: 0804-HY-156467A-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-156467A-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Neladalkib TFA is the TFA salt form of Neladalkib (HY-156467) . Neladalkib (NVL-655) is an oral ALK inhibitor, the IC50 for Neladalkib in inhibiting ALK is 2.8 nM. Neladalkib promotes cell apoptosis and has anti-tumor activity[1][2].
Product Name Alternative
NVL-655 (TFA)
UNSPSC
12352005
Target
Anaplastic lymphoma kinase (ALK) ; Apoptosis
Type
Reference compound
Related Pathways
Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/alk-in-27-tfa.html
Purity
99.70
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCN1C2=C(C(Cl)=N1)CC3=CN(C)N=C3C4=CC=C(F)C=C4[C@H](OC5=C(N)N=CC2=C5)C.OC(C(F)(F)F)=O
Molecular Formula
C25H23ClF4N6O3
Molecular Weight
566.94
References & Citations
[1]Jennifer Anne Green, et al. Methods of treating solid tumor using (19r) -5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1 (24),2 (6),4,8,11,13,15,17,21 (25),22-decaen-22-amine. WO2023196910A1. |[2]Jessica J Lin, et al. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov. 2024 Sep 13:OF1-OF20.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Popular Products